

CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

PRODUCT NAME:	SAMPLE ID:
Strength:	Expiration Date:
Lot Number:	Total Quantity Produced:

PHYSICAL PROPERTIES	STATUS (PASS/FAIL)	METHOD
Appearance		
Color		
Aroma		

CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
THCV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Unit Weight		
THC by Mass		

OTHER ACTIVE INGREDIENTS**	MG/UNIT	METHOD
Palmitoylethanolamide (PEA)		

HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES***	STATUS (PASS/FAIL)	METHOD
Total Pesticides		

RESIDUAL SOLVENTS***	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.†

†Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Advanced Botanical Consulting & Testing Sample ID #:


**Actual analytical results obtained by Advanced Botanical Consulting & Testing, Inc. (Tustin, CA), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

***Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

**This Certificate of Analysis has been generated to document product test results.
The "Prepared By" signature does not indicate finished product release for distribution.**

QUALITY APPROVAL

Prepared By / Date	Approved By / Date	Status
Vandana Kothari	 Signed by Vandana Kothari I approve this document 17-Jan-2025 11:30 PST 87A410FFF032487389008EED0868E359	PASS



January 14, 2025

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 565709
Sample No. 1269194

SAMPLE INFORMATION

Description FP-25-0003 Relief Softgels 60ct SKU 608 exp 07/26
Lot Number 52631
Category (Type) Non-Inhalable Edible (Capsule)
Received January 10, 2025

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant) ✔ Pass
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date January 10, 2025 to January 14, 2025

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
Δ8-THC	ND	ND	ND	ND	-
Δ9-THC	<LOQ	<LOQ	<LOQ	<LOQ	Pass
Δ9-THCA	ND	ND	ND	ND	-
THCV	ND	ND	ND	ND	-
THCVA	ND	ND	ND	ND	-
CBD	28.04	2.804	23.85	1430.95	-
CBDA	14.12	1.411	12.00	720.20	-
CBC	ND	ND	ND	ND	-
CBCA	ND	ND	ND	ND	-
CBDV	0.41	0.041	0.35	20.84	-
CBG	ND	ND	ND	ND	-
CBGA	<LOQ	<LOQ	<LOQ	<LOQ	-
CBN	ND	ND	ND	ND	-
Total THC	<LOQ	<LOQ	<LOQ	<LOQ	-
Total CBD	40.42	4.042	34.38	2062.57	-
Total Cannabinoids	40.83	4.083	34.72	2083.41	-
Sum of Cannabinoids	42.57	4.257	36.20	2171.99	-
Serving Weight (g)	0.8504				
Package Weight (g)	51.02				

Reported results and measurements are based off of a calculated hypothetical weight using the ratio between filling weight and total capsule weight as per client instruction. Only the filling material was tested.

Comments

Reported by
Anresco, Inc.

Ricky Liang
Ricky Liang
Analyst II



ND = None Detected
LOD = Limit of Detection (0.1333 mg/g)
LOQ = Limit of Quantitation (0.4000 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

January 14, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

January 14, 2025

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 565709
 Sample No. 1269194

SAMPLE INFORMATION

Description FP-25-0003 Relief Softgels 60ct SKU 608 exp 07/26
Lot Number 52631
Category (Type) Non-Inhalable Edible (Capsule)
Received January 10, 2025

ANALYTICAL RESULTS

Analysis Pesticide Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date January 10, 2025 to January 14, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation

Seonmin Lee
Analyst II



January 14, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

January 14, 2025

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 565709
Sample No. 1269194

SAMPLE INFORMATION

Description FP-25-0003 Relief Softgels 60ct SKU 608 exp 07/26
Lot Number 52631
Category (Type) Non-Inhalable Edible (Capsule)
Received January 10, 2025

ANALYTICAL RESULTS

Analysis Residual Solvent Screen ✔ Pass
Instrument Gas Chromatography Mass Spectrometry (GC/MS)
Method MF-CHEM-32
Analysis Date January 10, 2025 to January 14, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation


Alma Dorantes
Analyst I



January 14, 2025

If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

January 14, 2025

CV SCIENCES, INC.
 9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 565709
 Sample No. 1269194

SAMPLE INFORMATION

Description FP-25-0003 Relief Softgels 60ct SKU 608 exp 07/26
Lot Number 52631
Category (Type) Non-Inhalable Edible (Capsule)
Received January 10, 2025

ANALYTICAL RESULTS

Analysis Mycotoxins Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date January 10, 2025 to January 14, 2025

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by
Anresco, Inc.

ND = None Detected
 LOD = Limit of Detection
 LOQ = Limit of Quantitation

1/14/25

 Seonmin Lee
 Analyst II

January 14, 2025

If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

January 17, 2025

CV SCIENCES, INC.
 9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 565709
 Sample No. 1269194

SAMPLE INFORMATION

Description FP-25-0003 Relief Softgels 60ct SKU 608 exp 07/26
Lot Number 52631
Received January 10, 2025

ANALYTICAL RESULTS

Analysis Date January 10, 2025 to January 17, 2025

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /25g	MF-MICRO-11 (AOAC 2016.01)
	Staph aureus	Negative /25g	USP <62>

Reported by
Anresco, Inc.



Allen Zhu
 Analyst

If there are any questions with this report, please contact "compliance@anresco.com".

page 1 of 1

January 14, 2025

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 565709
Sample No. 1269194

SAMPLE INFORMATION

Description FP-25-0003 Relief Softgels 60ct SKU 608 exp 07/26
Lot Number 52631
Category (Type) Non-Inhalable Edible (Capsule)
Received January 10, 2025

ANALYTICAL RESULTS

Analysis Heavy Metals ✔ Pass
Instrument Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method MF-CHEM-16
Analysis Date January 10, 2025 to January 14, 2025

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.125	ND	0.5	Pass

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation



Eric Tam
Senior Chemist

January 14, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate Of Completion

Envelope Id: BC488809-D1D9-4336-AA9C-B3A4B962199A	Status: Completed
Subject: FP-25-0003 Relief Softgels 60ct SKU 608 exp 07/26 52631	
Source Envelope:	
Document Pages: 9	Signatures: 1
Certificate Pages: 1	Initials: 0
AutoNav: Enabled	Envelope Originator: Vandana Kothari vandana.kothari@cvsciences.com
Envelopeld Stamping: Enabled	IP Address: 64.207.219.135
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	

Record Tracking

Status: Original 1/17/2025 11:27:08 AM	Holder: Vandana Kothari vandana.kothari@cvsciences.com	Location: DocuSign
---	---	--------------------

Signer Events

Vandana Kothari
vandana.kothari@cvsciences.com
DIRECTOR OF QUALITY
CV Sciences - Part 11
Security Level: Email, Account Authentication (Required)

Signature

Vandana Kothari

Signature Adoption: Pre-selected Style
Signature ID:
87A410FF-F032-4873-8900-BEED0868E359
Using IP Address: 75.85.176.253

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Timestamp

Sent: 1/17/2025 11:27:52 AM
Viewed: 1/17/2025 11:30:18 AM
Signed: 1/17/2025 11:30:53 AM

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent	Hashed/Encrypted	1/17/2025 11:27:52 AM
Certified Delivered	Security Checked	1/17/2025 11:30:18 AM
Signing Complete	Security Checked	1/17/2025 11:30:53 AM
Completed	Security Checked	1/17/2025 11:30:53 AM

Payment Events

Status

Timestamps